SPY299.08+3.64 1.23%
DIA250.25+5.37 2.19%
IXIC9,340.22+15.63 0.17%

UPDATE: SVB Leerink Upgrades CymaBay Therapeutics To Outperform, Raises Target To $6 Notes Seladelpar 'findings are a near-best case scenario for CBAY, in our view, and would appear to reopen the door to develop seladelpar in both PBC and NASH'

Benzinga · 05/12/2020 16:23